|RxNews Recap for Friday 11-27-09|
|By Mary Davila|
|Friday, 27 November 2009 20:53|
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of software for pharmaceutical discovery and development, announced that it expects to file its 10K-SB Annual report with the Securities and Exchange Commission on Monday, November 30, for the 2009 fiscal year ended August 31, 2009.
PanGenex Corporation (OTC:PGCX) (“PanGenex” or “the Company”) announced today that it anticipates the release of its long form television program, demonstrating the benefits of Calci-CLEAR™, its patent pending dietary supplement that addresses soft tissue calcification, pursuant to its partnership with Incredible Discoveries® in early 2010.
XenaCare Holdings, Inc. (OTC:XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that is has become a national sponsor of the Arthritis Foundation at the National Proud Sponsor level.
Celgene Corporation (NASDAQ:CELG) today announced its presentation at the NASDAQ OMX 23rd Investor Program on Tuesday, December 1, 2009 at 8:30 a.m. GMT will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company.
Phase Forward (NASDAQ:PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its chairman and chief executive officer, Bob Weiler, and senior vice president and chief financial officer, Chris Menard, will present at the 21st Annual Piper Jaffray Health Care Conference at the New York Palace Hotel in New York City.
All figures are in CDN$ Chai-Na-Ta Corp. (OTC:CCCFF), one of the world's largest suppliers of North American ginseng, today announced a third quarter 2009 net loss of $136,000, or less than $0.01 per basic share, compared to a net loss of $2.0 million, or $0.06 per basic share, in the same period last year.
ALDA Pharmaceutical Corp. (OTC:APCSF) ("the Company" or "ALDA") announces that it has entered into an agreement with Shoppers Drug Mart Corporation ("Shoppers") that will make the Company's T36® Antiseptic Hand Sanitizer available in over 1,170 Shoppers Drug Mart and Pharmaprix stores across Canada.
Theravance, Inc. (NASDAQ:THRX) announced today that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) related to the telavancin New Drug Application (NDA) for the treatment of nosocomial pneumonia (NP).